Clinical Trials Logo

Filter by:
NCT ID: NCT04003181 Completed - Diarrhea Clinical Trials

The Pathogenesis of Chronic Diarrhoea After Treatment for Cancer in Cecum and the Ascending Colon

Start date: September 28, 2017
Phase: N/A
Study type: Interventional

Many patients suffer from chronic diarrhoea after surgical treatment for cancer in the right side of the colon. The investigators' main hypothesis is that colon cancer patients with chronic diarrhoea have a higher risk of bile acid malabsorption compared with colon cancer patients without diarrhoea. The investigators also expect that a part of the cases of bile acid malabsorption is caused by underlying bacterial overgrowth in the small bowel. The investigators assume that patients with severe bile acid malabsorption have a lower value of FGF19 in the blood compared to patients with moderate or none bile acid malabsorption. Furthermore, it is assumed that patients with chronic diarrhoea and documented bile acid malabsorption after surgical treatment for right-sided colon cancer will get improved bowel function when treated with a bile acid binder, or antibiotics in case of bacterial overgrowth.

NCT ID: NCT04001218 Completed - Healthy Clinical Trials

Head Repositioning Accuracy During Experimental Neck Pain

Start date: April 9, 2015
Phase: N/A
Study type: Interventional

This study investigates if/how an experimentally applied neck muscle pain influences head repositioning error in healthy participants.

NCT ID: NCT04001127 Completed - Cancer Clinical Trials

High Intensity Functional Training in the Rehabilitation of Cancer Survivors

Start date: August 6, 2019
Phase: N/A
Study type: Interventional

The primary aim of this study is to investigate changes in health related quality of life (HRQoL) and cancer-related fatigue (CRF) following a 16-weeks of HIFT as a part of the rehabilitation of cancer survivors. Additionally, we will investigate the continuation of participation in any High Intensity Functional Training (HIFT) program, three as well as 12 months following completion of the exercise intervention. The intervention containing high intensity functional training will take place in a pragmatic clinical setting at the Center for Cancer and Health in Copenhagen. We hypothesize that the HIFT will be be associated with improved HRQoL and CRF.

NCT ID: NCT03997773 Completed - Quality of Life Clinical Trials

Face-it: Health Promotion for Women With Prior Gestational Diabetes

Face-it
Start date: May 21, 2019
Phase: N/A
Study type: Interventional

This project focuses on evaluating a health promotion intervention among families where the mother has prior gestational diabetes mellitus (GDM) in the first year after delivery. The intervention focuses on the individual, family and health system levels. The aim is to increase quality of life and reduce the risk of type 2 diabetes among women with prior GDM and their families.

NCT ID: NCT03997721 Completed - Fluid Overload Clinical Trials

Pathophysiology of Perioperative Fluid Management in Emergency Laparotomy

Start date: May 23, 2019
Phase:
Study type: Observational [Patient Registry]

Pathophysiology of perioperative fluid management in patients undergoing emergency laparotomy.

NCT ID: NCT03996382 Completed - Clinical trials for Carpal Tunnel Syndrome

Prevalence of Wild Type Transthyretin Cardiac Amyloidosis in Patients Operated for Idiopathic Carpal Tunnel Syndrome

CACTuS
Start date: June 17, 2019
Phase: N/A
Study type: Interventional

Wild-type transthyretin cardiac amyloidosis is an underdiagnosed depository disease in which fibril monomers of misfolded amyloid protein accumulates in various tissues, including the heart, and cause tissue dysfunction. Before onset of cardiac symptoms, many patients will have undergone surgery for idiopathic carpal tunnel syndrome since the protein also deposits in the transversal carpal ligament of the hand. This study investigates patients previously operated for idiopathic carpal tunnel syndrome to determine if they display signs and symptoms of cardiac amyloidosis.

NCT ID: NCT03996369 Completed - Ulcerative Colitis Clinical Trials

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

ELEVATE UC 12
Start date: September 15, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy of etrasimod on clinical remission in participants with moderately to severely active ulcerative colitis (UC).

NCT ID: NCT03995771 Completed - Knee Pain Clinical Trials

Adolescent Knee Pain (AK-Pain) Prognostic Tool

Start date: July 1, 2019
Phase:
Study type: Observational [Patient Registry]

The overall aim of this study is to develop and test a prognostic tool for knee pain in children and adolescents to be used in general practice. By using the tool, general practitioners will be able to allocate the patient to a category of risk (e.g. low/medium/high) of recurrent or persistent knee pain at 3 months and 6 months, and to subsequently provide a treatment that is specific to the category of risk of the patient.

NCT ID: NCT03993132 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Start date: October 1, 2018
Phase:
Study type: Observational

The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).

NCT ID: NCT03989817 Completed - Headache Disorders Clinical Trials

The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers

Start date: June 14, 2019
Phase: N/A
Study type: Interventional

Vasoactive intestinal peptide (VIP) is a peptide of 28 amino acid residues that belongs to the glucagon/secretin superfamily of peptides. It is produced in different regions of the nervous system, including the brain, trigeminovascular system and several autonomic nerves. Once released from neurons, it acts on vasoactive intestinal peptide receptor 1 (VPAC1), vasoactive intestinal peptide receptor 2 (VPAC2) and pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1), by mediating smooth muscle relaxation, vasodilation and water secretion. Along with other neuropeptides, such as calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide (PACAP), it is released from the trigeminal afferents and exerts a strong vasodilating activity on the cranial vasculature, sharing the activation of adenylate cyclase. Especially, it shares 70% structure with PACAP and acts on the same receptors. But, unlike it, VIP cannot induce a long-lasting vasodilation and has a modest capability to induce migraine attacks. Whether a long-lasting infusion of VIP may induce a prolonged vasodilation in the cerebral vessels and migraine, as a twenty-minute infusion of PACAP, is unknown.